Evaluation of Cagrilintide on Bone Metabolism in Post-Menopausal Women with Obesity

The primary objective of the study is to evaluate the role of the **amylin analogue cagrilintide** in bone metabolism among post-menopausal females with obesity. This is clinically relevant as it may provide insights into potential therapeutic strategies for managing bone health in this specific population, which is at increased risk for osteoporosis and related complications due to hormonal changes and increased body mass index (BMI ≥ 30.0 kg/m²).

The clinical trial involves a study population of **female** participants aged between 50 and 70 years, all of whom are in a post-menopausal state. The participants are characterized by **obesity**, with a body mass index (BMI) of 30.0 kg/m² or higher at the time of screening. The post-menopausal status is defined by 12 months of amenorrhea, elevated levels of follicular stimulating hormone (FSH) ranging from 16 to 130 UI/L, and reduced levels of anti-Müllerian hormone (AMH) and inhibin B. The trial does not include male subjects or any vulnerable populations. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet or physical activity. The selection criteria focus on the specified age range and health status, ensuring a homogenous group for the study.

The clinical trial is designed to evaluate the effects of the **amylin analogue cagrilintide** on bone metabolism in post-menopausal women with obesity. This study is a Phase 3, randomized, double-blind, controlled trial. The estimated recruitment start date is May 5, 2025, with an anticipated end date of November 24, 2027. Participants will be involved in the study for the duration of the trial, which spans approximately two and a half years.

The trial will commence with an inclusion (screening) visit to assess eligibility based on specific criteria, including age, body mass index (BMI), and post-menopausal status. Eligible participants will then be randomized into either the treatment group receiving cagrilintide or a control group. The study will include multiple follow-up visits to monitor the participants' health, adherence to the protocol, and any potential side effects. These visits will also involve the collection of data pertinent to the study's objectives, such as bone density measurements and metabolic assessments.

The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to evaluate the long-term effects of the treatment. Participants may be withdrawn from the study early if they experience adverse effects, fail to comply with the study protocol, or choose to withdraw consent. The trial's design ensures rigorous monitoring and data collection to achieve its objectives while maintaining participant safety and scientific integrity.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the absence of specific details, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be included. The data does not contain any information about the **pharmaceutical form** or the **dosage** of the investigational product, nor does it specify the **route of administration** or the **frequency** with which the medication should be administered. Furthermore, there is no information on whether the product is a **paediatric formulation** or if it has an **orphan drug** designation.

As the source data lacks comprehensive details, it is not possible to provide a complete description of the treatments used in this clinical trial. The information provided is insufficient to outline the specifics of the investigational product or any comparator treatments that may be involved in the study.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on May 5, 2025, with an estimated completion date of November 24, 2027. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology to measure, collect, and analyze these efficacy parameters at predetermined timepoints throughout the study duration. The trial's design and execution will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy assessments.